Marinomed Biotech AG

BRIEF

published on 03/01/2024 at 07:50, 8 months 22 days ago

Marinomed Biotech AG Announces New Head of Investor & Public Relations

Investor Relations Corporate Announcement Marinomed Biotech Public Relations Lucia Ziegler
PRESS RELEASE

published on 03/01/2024 at 07:45, 8 months 22 days ago

Marinomed Biotech AG: Lucia Ziegler new Head of Investor & Public Relations
Marinomed Biotech AG appoints Lucia Ziegler as new Head of Investor & Public Relations, integrating IR activities with PR for better stakeholder communication

Investor Relations Marinomed Biotech AG Public Relations Lucia Ziegler Stakeholder Communication
PRESS RELEASE

published on 02/14/2024 at 07:45, 9 months 9 days ago

Marinomed Biotech AG announces preliminary revenue for 2023
Marinomed Biotech AG announces preliminary revenue for 2023, with cash stability through cost management and funding program. Outlook includes new product launches and market expansions

Marinomed Biotech AG Preliminary Revenue Cash Management Product Launches Market Expansion
PRESS RELEASE

published on 02/07/2024 at 07:45, 9 months 16 days ago

Marinomed Biotech AG with important progress for Carragelose in 2024
Marinomed Biotech AG enrolls first patient in clinical study for Carragelose eye drops and receives patents in Singapore, South Korea, and Brazil, strengthening its IP portfolio. The company plans to launch Carragelose eye drops and nasal spray in 2024, targeting allergy and eye care markets

Clinical Study Marinomed Biotech AG Carragelose Patents Allergy And Eye Care Markets
PRESS RELEASE

published on 10/17/2023 at 07:45, 1 year 1 month ago

Marinomed Biotech AG resumes Nice & Green Convertible Notes Funding Program with reduced volume
PRESS RELEASE

published on 08/17/2023 at 07:45, 1 year 3 months ago

Marinomed Biotech AG reports record revenues in the first half of the year and pushes business development activities
PRESS RELEASE

published on 08/09/2023 at 07:45, 1 year 3 months ago

Marinomed enters first long-term Solv4U partnership with Shanghaibased SPH Sine Pharmaceutical Laboratories Co. Ltd.
PRESS RELEASE

published on 07/27/2023 at 07:45, 1 year 3 months ago

Marinomed Biotech AG: M8 Pharmaceuticals obtains market authorization for Carragelose nasal spray in Mexico
PRESS RELEASE

published on 07/13/2023 at 07:45, 1 year 4 months ago

Peer-reviewed publication by Marinomed Biotech AG and Friedrich-Alexander-University Erlangen-Nürnberg reconfirms broad virus-blocking effectiveness of iota-carrageenan
PRESS RELEASE

published on 06/21/2023 at 17:00, 1 year 5 months ago

Marinomed Biotech AG: Annual General Meeting elects Dr. Eva Hofstädter-Thalmann as a new member of the Supervisory Board

Published on 11/22/2024 at 23:55, 1 day 3 hours ago

Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 1 day 3 hours ago

Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 1 day 4 hours ago

Kidoz Inc. Announces Results of 2024 AGM
Published on 11/22/2024 at 23:05, 1 day 4 hours ago

Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 1 day 4 hours ago

Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.

View all ACCESSWIRE

Published on 11/22/2024 at 18:14, 1 day 9 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 18:00, 1 day 9 hours ago

Holding(s) in Company
Published on 11/22/2024 at 17:53, 1 day 9 hours ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 1 day 10 hours ago

EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 1 day 11 hours ago

Proposed cancellation of admission to trading

View all EQS

Published on 11/22/2024 at 14:35, 1 day 12 hours ago

Thales Press release
Published on 11/21/2024 at 06:58, 2 days 20 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 3 days 8 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 3 days 9 hours ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 3 days 9 hours ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024

View all LES ECHOS COMFI WIRE

News